| Publication number |
CLPUB00781 |
|---|
| Authors |
Jenkins D.E., Hornig Y.S., Oei Y.A., Yu S.-F., Dusich J.M., Purchio A.F. |
|---|
| Title |
Luciferase-expressing MCF-7-luc-F5 human breast cancer cells used to monitor mammary fat pad tumor growth and metastasis in vivo in nude-beige mice. |
|---|
| Citation |
Cancer Res. 64 Suppl. 7:1179-1180(2004) |
|---|
| Web pages |
https://aacrjournals.org/cancerres/article/64/7_Supplement/1179/516584 |
|---|
| Abstract |
A clonal human tumor cell line expressing firefly luciferase,
MCF-7-luc-F5, was developed from parental MCF-7 breast carcinoma
cells and characterized for bioluminescence in vitro and in vivo.
As few as twenty cells were detectable in vitro and average
bioluminescence measured approximately 680 photons/sec/cell.
Tumorigenesis of MCF-7-luc-F5 cells was assessed with and
without estrogen supplement in vivo following injection of cells
into the mammary fat pad of nude-beige mice. Continuous tumor
growth was observed by weekly bioluminescent imaging in mice
receiving a slow release (60 day) estrogen pellet implant (0.36
mg/pellet), while no tumor growth occurred in mice without
estrogen supplement. Caliper measurements of tumor volume
indicated similar results. A kinetic analysis of luciferase
activity in vivo demonstrated that peak signals were evident
approximately 12-15 minutes after injection of luciferin
substrate and were maintained at a relatively stable level for
at least another 20-25 minutes. Spontaneous metastasis from the
primary mammary fat pad tumor to thoracic and axillary regions
was observed in vivo in 50% of the animals. Subsequent ex vivo
images and histology identified metastatic sites in lung, rib,
or lymph nodes depending on the mouse. Standard drug treatment
on primary and secondary tumor growth was also monitored by
bioluminescent imaging.
|
|---|
| Cell lines |
CVCL_5J35; MCF-7-luc-F5 |
|---|
